Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial

BACKGROUND: Immune checkpoint blockade with monoclonal antibodies targeting programmed death 1 (PD-1) and its ligand PD-L1 has played a major role in the rise of cancer immune therapy. We have identified naturally occurring self-reactive T cells specific to PD-L1 in both healthy donors and cancer pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Jørgensen, Nicolai Grønne, Klausen, Uffe, Grauslund, Jacob Handlos, Helleberg, Carsten, Aagaard, Thomas Granum, Do, Trung Hieu, Ahmad, Shamaila Munir, Olsen, Lars Rønn, Klausen, Tobias Wirenfeldt, Breinholt, Marie Fredslund, Hansen, Morten, Martinenaite, Evelina, Met, Özcan, Svane, Inge Marie, Knudsen, Lene Meldgaard, Andersen, Mads Hald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680803/
https://www.ncbi.nlm.nih.gov/pubmed/33240282
http://dx.doi.org/10.3389/fimmu.2020.595035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680803/
https://www.ncbi.nlm.nih.gov/pubmed/33240282
http://dx.doi.org/10.3389/fimmu.2020.595035

Ejemplares similares